Partial
Partial Misalignment
Patient Risk:
Moderate
Summary
The response aligns with several label-supported facts (drug identity/class, LDL-C reduction indications, subcutaneous administration and 75 mg strength content, and availability of 75 mg/150 mg). However, it cannot be fully verified against the FDA label because key safety/administration elements are not supported by the provided label excerpts, and it includes claims implying absence of specific adverse reactions (injection-site/systemic flu-like symptoms) that are plausibly covered in other label sections not included.
Category Scores
Accurate Statements
Praluent is a monoclonal antibody.
Section 11 (Alirocumab is a human monoclonal antibody).
Praluent is used to reduce low-density lipoprotein cholesterol (LDL-C).
Section 1 (adjunct to diet and exercise to reduce LDL-C).
The “75 mg” strength refers to the dose delivered by the prefilled pen or syringe.
Section 11 (Each 75 mg/mL pre-filled pen contains 75 mg alirocumab) and Section 3 (75 mg/mL pre-filled pen).
Praluent also comes in other strengths.
Section 3 (available as 75 mg/mL and 150 mg/mL).
The key difference between Praluent strengths is the amount of medication delivered each injection.
Section 3 and Section 11 (each pre-filled pen contains 75 mg or 150 mg alirocumab).
Unsupported Statements
Praluent is a prescription cholesterol-lowering injection (alirocumab).
The provided label excerpts do not explicitly state the word “prescription.”
Praluent 75 mg is typically given subcutaneously on a regular schedule.
Label supports a subcutaneous dosing interval (e.g., 75 mg once every 2 weeks) but the excerpt does not support the word “typically.”
Patients may receive Praluent by self-injection under clinician guidance.
Section 2.4 in the excerpts supports training for patients/caregivers and instruction to prepare/administer, but it does not explicitly use the phrasing “self-injection” or “clinician guidance.”
Dose and frequency are set to meet LDL-C targets.
Label supports LDL-C measurement prior to next scheduled dose and possible dosage adjustment if response is inadequate, but does not explicitly describe “targets.”
The appropriate dose is based on clinician assessment of LDL-C response and overall treatment goals.
Label supports LDL-C–guided measurement/adjustment, but does not explicitly mention “overall treatment goals.”
Contradictions
Important Omissions
Key label safety/usage elements (e.g., boxed warning, contraindications, full warnings/precautions, and specific adverse reactions) were not addressed or verified; additionally, the AI response mentions injection-site/systemic reactions without label-backed detail in the provided excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes claims about injection-site reactions/systemic flu-like symptoms without the provided label excerpts substantiating those statements, and it does not verify major safety sections (contraindications/warnings/boxed warning/adverse reactions) that are required for label-accurate compliance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partial Misalignment
Primary Issue
Several phrases are not explicitly supported by the provided FDA label excerpts (e.g., “typically,” “self-injection under clinician guidance,” “LDL-C targets,” “overall treatment goals”), and the response includes safety-style reaction statements without confirming the relevant adverse reaction content from the label excerpts.
Suggested Improvement
Use label-verbatim language where possible (e.g., dosing intervals and subcutaneous administration), replace unsupported wording (remove “typically/targets/overall treatment goals/self-injection/clinician guidance” unless explicitly stated), and ground any adverse reaction statements in the specific Adverse Reactions/Warnings sections from the full label.